Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD - Jaramillo Segura, Sonia; Le Cornet, Lucian; Kratzmann, Markus; Krisam, Johannes; Görner, Martin; Hänel, Mathias; Röllig, Christoph; Wass, Maxi; Scholl, Sebastian; Ringhoffer, Mark; Reichart, Alexander; Steffen, Björn; et al. (Trials, 2023)
Veröffentlicht: 15. September 2023